Funding Received
$19 Million in 2 Rounds from 7 Investors
Most Recent Funding
$4 Million Debt Financing on June 11, 2014
Headquarters:
La Jolla, CA
Description:
RuiYi is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s
Categories:
Biotechnology
Website:
http://ruiyibio.com

Detailed Description

Update

RuiYi is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.

Current Team (8)

Update

Board Members and Advisors (10)

Update

Investors (7)

Update

Offices/Locations (2)

Update
  • China Office

    1043 Halei Rd, Suite 502

    Zhangjiang Hi-tech Park

    Shanghai, 201203

    CHN

  • Office

    505 Coast Blvd S.

    Suite 300

    La Jolla, CA 92037

    USA

Images (1)

Update
  • 163e6ea948aaeee655f9533abb8f370e